Skip to main content

Table 1 Baseline characteristics of MAPT-NI groups

From: The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial

 

TEP-FDG (n = 67)

  

Primary population

Secondary and exploratory populations

 

Overall population (n = 67)

No MI (n = 33)

MI (n = 34)

No omega-3 (n = 29)

Omega-3 (n = 38)

Omega-3 + MI (n = 20)

Omega-3 only (n = 18)

MI only (n = 14)

Placebo (n = 15)

Male gender, N (%)

18 (26.87)

8 (24.24)

10 (29.41)

8 (27.59)

10 (26.32)

7 (35.00)

3 (16.67)

3 (21.43)

5 (33.33)

Age in years, mean (SD)

76.37 (4.23)

76.79 (4.24)

75.97 (4.24)

75.41 (4.37)

77.11 (4.02)

77.10 (4.15)

77.11 (3.98)

74.36 (3.95)

76.40 (4.64)

BMI (kg/m2), mean (SD)

26.40 (3.51)

26.60 (3.97)

26.21 (3.06)

26.35 (2.99)

26.44 (3.91)

26.34 (3.73)

26.56 (4.20)

26.04 (1.84)

26.65 (3.82)

Education, N (%)

 No diploma or primary school certificate

18 (27.27)

9 (27.27)

9 (27.27)

6 (21.43)

12 (31.58)

7 (35.00)

5 (27.78)

2 (15.38)

4 (26.67)

 Secondary education

21 (31.82)

11 (33.33)

10 (30.30)

7 (25.00)

14 (36.84)

6 (30.00)

8 (44.44)

4 (30.77)

3 (20.00)

 High-school diploma

9 (13.64)

4 (12.12)

5 (15.15)

6 (21.43)

3 (7.89)

2 (10.00)

1 (5.56)

3 (23.08)

3 (20.00)

 University level

18 (27.27)

9 (27.27)

9 (27.27)

9 (32.14)

9 (23.68)

5 (25.00)

4 (22.22)

4 (30.77)

5 (33.33)

APOE4 carrier, N (%)

8 (13.79)

4 (13.33)

4 (14.29)

5 (20.00)

3 (9.09)

2 (12.50)

1 (5.88)

2 (16.67)

3 (23.08)

Composite cognitive score, mean (SD)

0.05 (0.69)

− 0.02 (0.71)

0.11 (0.68)

0.08 (0.58)

0.02 (0.77)

0.02 (0.80)

0.03 (0.77)

0.24 (0.46)

− 0.07 (0.66)

MMSE total score/30, mean (SD)

28.19 (1.62)

28.21 (1.71)

28.18 (1.55)

28.45 (1.40)

28.00 (1.76)

28.20 (1.54)

27.78 (1.99)

28.14 (1.61)

28.73 (1.16)

MMSE orientation score/10, mean (SD)

9.84 (0.41)

9.82 (0.39)

9.85 (0.44)

9.83 (0.38)

9.84 (0.44)

9.85 (0.49)

9.83 (0.38)

9.86 (0.36)

9.80 (0.41)

CDR score, N (%)

 CDR = 0

27 (40.30)

14 (42.42)

13 (38.24)

12 (41.38)

15 (39.47)

8 (40.00)

7 (38.89)

5 (35.71)

7 (46.67)

 CDR = 0.5

40 (59.70)

19 (57.58)

21 (61.76)

17 (58.62)

23 (60.53)

12 (60.00)

11 (61.11)

9 (64.29)

8 (53.33)

FCSRT scores, mean (SD)

 Free recall/48

28.30 (6.81)

27.67 (7.47)

28.91 (6.16)

28.79 (6.22)

27.92 (7.29)

27.90 (6.54)

27.94 (8.25)

30.36 (5.47)

27.33 (6.69)

 Total recall/48

45.34 (3.45)

45.03 (3.23)

45.65 (3.68)

45.38 (3.00)

45.32 (3.79)

45.15 (4.25)

45.50 (3.33)

46.36 (2.65)

44.47 (3.11)

 Delayed free recall/16

10.93 (2.66)

10.82 (3.00)

11.03 (2.33)

11.21 (2.06)

10.71 (3.06)

10.90 (2.55)

10.50 (3.60)

11.21 (2.04)

11.20 (2.14)

 Delayed total recall/16

15.61 (0.85)

15.48 (1.06)

15.74 (0.57)

15.79 (0.49)

15.47 (1.03)

15.75 (0.55)

15.17 (1.34)

15.71 (0.61)

15.87 (0.35)

TMT A, mean (SD)

44.78 (13.95)

45.03 (15.38)

44.53 (12.63)

43.52 (11.11)

45.74 (15.85)

45.30 (13.59)

46.22 (18.44)

43.43 (11.53)

43.60 (11.11)

TMT B, mean (SD)

114.36 (36.35)

116.03 (41.27)

112.74 (31.48)

108.56 (35.06)

118.97 (37.20)

119.22 (29.85)

118.69 (45.11)

103.77 (32.63)

113.00 (37.84)

Code test score, mean (SD)

38.19 (9.20)

37.97 (8.88)

38.41 (9.63)

37.90 (8.89)

38.42 (9.55)

37.75 (9.69)

39.17 (9.61)

39.36 (9.83)

36.53 (8.01)

COWAT score, mean (SD)

19.66 (6.24)

19.18 6.59)

20.12 (5.94)

20.34 (6.34)

19.13 (6.20)

19.65 (6.39)

18.56 (6.10)

20.79 (5.38)

19.93 (7.28)

CNT score, mean (SD)

25.70 (8.53)

24.94 (8.62)

26.44 (8.51)

26.52 (7.82)

25.08 (9.09)

25.45 (9.00)

24.67 (9.44)

27.86 (7.86)

25.27 (7.83)

ADCS-ADL PI /45; mean (SD)

40.00 (4.72)

39.27 (5.43)

40.73 (3.83)

40.45 (4.54)

39.65 (4.89)

40.00 (4.16)

39.28 (5.65)

41.71 (3.22)

39.27 (5.34)

GDS, mean (SD)

2.33 (1.85)

2.67 (1.67)

2.00 (1.98)

2.41 (2.01)

2.26 (1.75)

1.90 (1.74)

2.67 (1.71)

2.14 (2.35)

2.67 (1.68)

AD-based SUVr, mean (SD)

1.13 (0.10)

1.12 (0.08)

1.14 (0.11)

1.12 (0.1)

1.14 (0.09)

1.14 (0.11)

1.13 (0.08)

1.13 (0.11)

1.11 (0.09)

DHA (μg/g RBC), mean (SD)

5.82 (1.41)

5.66 (1.39)

5.98 (1.43)

5.69 (1.24)

5.92 (1.55)

5.97 (1.75)

5.88 (1.36)

6.00 (0.94)

5.41 (1.44)

Medial temporal lobe atrophy, N (%)

 Stage 0

17 (25.37)

6 (18.18)

11 (32.35)

8 (27.59)

9 (23.68)

4 (20)

5 (27.78)

7 (50)

1 (6.67)

 Stage 0.5

13 (19.40)

6 (18.18)

7 (20.59)

3 (10.34)

10 (26.32)

4 (20)

6 (33.33)

3 (21.43)

0 (0)

 Stage 1

25 (37.31)

14 (42.42)

11 (32.35)

13 (44.83)

12 (31.58)

8 (40)

4 (22.22)

3 (21.43)

10 (66.67)

 Stage 1.5

5 (7.46)

3 (0.09)

2 (5.88)

3 (10.34)

2 (5.26)

1 (5)

1 (5.56)

1 (7.14)

2 (13.33)

 Stage 2

7 (10.44)

4 (12.12)

3 (8.82)

2 (6.90)

5 (13.16)

3 (15)

2 (11.11)

0 (0)

2 (13.33)

  1. Medial temporal lobe atrophy is the average of the left and right medial temporal lobes atrophy
  2. Abbreviations: MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating score, ADCS-ADL PI Alzheimer’s Disease Cooperative Study-activities of daily living Prevention Instrument, TMT Trail Making Test, COWAT Controlled Oral Word Association Test, CNT Category Naming Test, GDS Geriatric Depression Scale, FCRST Free and Cued Selective Reminding Test, DHA docosahexaenoic acid, SUVr standardized uptake value relative